Edit
Bizwit-Logo-Final

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Global Generic Injectable Market to reach USD65.85 billion by 2027.

Global Generic Injectable Market Size study, by Product type (Monoclonal Antibodies, Immunoglobulin Generic injectable, Insulin Generic injectable, Blood Factors Generic injectable, Peptide Antibiotics Generic injectable, Vaccines Generic injectable, Chemotherapy Agents Generic injectable, Others) by Molecule Type (Small Molecule Generic injectable, Large Molecule Generic injectable) by Application (Oncology, Infectious Diseases, Diabetes, Blood Disorders, CNS Diseases, Cardiovascular Diseases, Others) by Route of Administration (Intravenous (IV) Generic injectable, Intramuscular (IM) Generic injectable, Subcutaneous (SC) Generic injectable) by Distribution channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) and Regional Forecasts 2020-2027.

Product Code: HALMD_66057708
Publish Date: 11-02-2021
Page: 200

Global Generic Injectable Market is valued approximately USD 30.72 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10 % over the forecast period 2020-2027. Generic injectables are bioequivalents of branded injectables and are not secured under medication patents. Since they have the same active ingredient, dose, strength, consistency, and type as the innovator drugs, they are both safe and efficient. While generic injectables are more difficult to manufacture, their research and development period is less expensive and shorter. Generic drug makers, unlike branded drug producers, do not need to invest millions of dollars in R&D and marketing. Furthermore, as opposed to oral generics, the number of entrants in the generic injectables industry is smaller, resulting in less price deflation and greater profit margins. The rising prevalence of chronic diseases has prompted developments in generic injectables research and development. The popularity of intravenous (IV) and intramuscular (IM) drug administration has grown in response to the need for urgent care alternatives. Insulin, for example, is best administered intramuscularly (IM). Generic injectable medicines have a range of benefits, including quicker licenses, more biologic medications in production pipelines, and a greater demand for injectable medication delivery. Drug sales opportunities for vaccinations, monoclonal antibodies, peptides, immunoglobulins, and antibodies are being bolstered by factors such as cost-effectiveness and improved health outcomes. Generic injectables are now becoming more widely accepted as more cost-effective drugs than their branded counterparts. Adoption rates for generic injectables are increasing as a result of these trends. A variety of causes, including family medical history, obesity, among others, are contributing to an increase in the prevalence of lifestyle-related diseases such as diabetes in both developed and developing countries. The rising incidence of diabetes raises medical costs associated with its treatment. According to WHO statistics, the prevalence of diabetes is projected to grow from 117 million in 2000 to 422.0 million in 2030, owing to an increase in patient numbers. Diabetes prevalence was calculated to be 2.8 percent in all age ranges in 2000, and is expected to increase to 4.4 percent by 2030. Additionally, the expiration of branded item patents and a decrease in the number of new product releases have benefited generic drugs and led to the growth of industry participants and product prices. As compared to the prices of premium drugs, generic injectables are comparatively inexpensive, giving a substantial boost to demand growth and still the net profits. Pfizer announced in July 2020 that it had reached an agreement to commit about US$ 465 million to the construction of a sterile injectable plant in Portage, Michigan. This growth is part of the company’s strategy to spend about $5 billion in each U.S.-based capital challenge in order to keep up with developments in the country’s corporate evaluation. However, manufacturing generic injectables necessitates sophisticated machinery, both of which must meet stringent registration and sterilisation requirements for – batch prior to output. Owing to the purchase/rent-to-lease of fixed assets, which results in high running expenses and debt ratios. Furthermore, compliance costs are considerably higher as a result of FDA requirements that high levels of safety be maintained not only throughout the production process, but also during processing, transportation, and delivery. This impedes the growth of the market over the forecast period of 2020-2027. Although, the expansion of large molecule products into injectables are fueling developments presenting a lucrative opportunity for the market.

The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical study of the global Generic Injectable market. North America is the leading region across the world in terms of market share owing to the well-established infrastructure and rising R&D expenditure. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate over the forecast period 2020-2027. Factors such as growth of government spending in pharmaceutical sectors would create lucrative growth prospects for the Generic Injectable market across Asia-Pacific region.

Major market player included in this report are:
Samsung Biologics Co Ltd
Aurobindo Pharma Limited
Sun Pharmaceutical Industries Ltd.
Novartis AG
Merck & Co. Inc.
Cipla Ltd
Pfizer Inc
Fresenius Kabi
Sanofi S.A
AstraZeneca Plc
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product type:
Monoclonal Antibodies
Immunoglobulin Generic injectable
Insulin Generic injectable
Blood Factors Generic injectable
Peptide Antibiotics Generic injectable
Vaccines Generic injectable
Chemotherapy Agents Generic injectable
Others
By Molecule Type:
Small Molecule Generic injectable
Large Molecule Generic injectable
By Application:
Oncology
Infectious Diseases
Diabetes
Blood Disorders
CNS Diseases
Cardiovascular Diseases
Others
By Route of Administration:
Intravenous (IV) Generic injectable
Intramuscular (IM) Generic injectable
Subcutaneous (SC) Generic injectable
By Distribution channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Generic Injectable Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Generic Injectable Market, by Region, 2018-2027 (USD Billion)
1.2.2. Generic Injectable Market, by Product Type, 2018-2027 (USD Billion)
1.2.3. Generic Injectable Market, by Molecule Type, 2018-2027 (USD Billion)
1.2.4. Generic Injectable Market, by Application, 2018-2027 (USD Billion)
1.2.5. Generic Injectable Market, by Route of Administration, 2018-2027 (USD Billion)
1.2.6. Generic Injectable Market, by Distribution Channel, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Generic Injectable Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Generic Injectable Market Dynamics
3.1. Generic Injectable Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of chronic diseases
3.1.1.2. The expiration of branded item patents and a decrease in the number of new product releases
3.1.2. Market Challenges
3.1.2.1. Complex manufacturing of generic injectables
3.1.2.2. Rising stringent regulation
3.1.3. Market Opportunities
3.1.3.1. Expansion of large molecule products into injectables
3.1.3.2. Investments on manufacturing capabilities by emerging countries
Chapter 4. Global Generic Injectable Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Generic Injectable Market, by Product Type
5.1. Market Snapshot
5.2. Global Generic Injectable Market by Product Type, Performance – Potential Analysis
5.3. Global Generic Injectable Market Estimates & Forecasts by Product Type 2017-2027 (USD Billion)
5.4. Generic Injectable Market, Sub Segment Analysis
5.4.1. Monoclonal Antibodies
5.4.2. Immunoglobulin Generic injectable
5.4.3. Insulin Generic injectable
5.4.4. Blood Factors Generic injectable
5.4.5. Peptide Antibiotics Generic injectable
5.4.6. Vaccines Generic injectable
5.4.7. Chemotherapy Agents Generic injectable
5.4.8. Others
Chapter 6. Global Generic Injectable Market, by Molecule Type
6.1. Market Snapshot
6.2. Global Generic Injectable Market by Molecule Type, Performance – Potential Analysis
6.3. Global Generic Injectable Market Estimates & Forecasts by Molecule Type 2017-2027 (USD Billion)
6.4. Generic Injectable Market, Sub Segment Analysis
6.4.1. Small Molecule Generic injectable
6.4.2. Large Molecule Generic injectable
Chapter 7. Global Generic Injectable Market, by Application
7.1. Market Snapshot
7.2. Global Generic Injectable Market by Application, Performance – Potential Analysis
7.3. Global Generic Injectable Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
7.4. Generic Injectable Market, Sub Segment Analysis
7.4.1. Oncology
7.4.2. Infectious Diseases
7.4.3. Diabetes
7.4.4. Blood Disorders
7.4.5. CNS Diseases
7.4.6. Cardiovascular Diseases
7.4.7. Others
Chapter 8. Global Generic Injectable Market, by Route of Administration
8.1. Market Snapshot
8.2. Global Generic Injectable Market by Route of Administration, Performance – Potential Analysis
8.3. Global Generic Injectable Market Estimates & Forecasts by Route of Administration 2017-2027 (USD Billion)
8.4. Generic Injectable Market, Sub Segment Analysis
8.4.1. Intravenous (IV) Generic injectable
8.4.2. Intramuscular (IM) Generic injectable
8.4.3. Subcutaneous (SC) Generic injectable
Chapter 9. Global Generic Injectable Market, by Distribution Channel
9.1. Market Snapshot
9.2. Global Generic Injectable Market by Distribution Channel, Performance – Potential Analysis
9.3. Global Generic Injectable Market Estimates & Forecasts by Distribution Channel 2017-2027 (USD Billion)
9.4. Generic Injectable Market, Sub Segment Analysis
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Drug Stores
9.4.4. Online Pharmacies
Chapter 10. Global Generic Injectable Market, Regional Analysis
10.1. Generic Injectable Market, Regional Market Snapshot
10.2. North America Generic Injectable Market
10.2.1. U.S. Generic Injectable Market
10.2.1.1. Product Type breakdown estimates & forecasts, 2017-2027
10.2.1.2. Molecule Type breakdown estimates & forecasts, 2017-2027
10.2.1.3. Application breakdown estimates & forecasts, 2017-2027
10.2.1.4. Route of Administration breakdown estimates & forecasts, 2017-2027
10.2.1.5. Distribution Channel breakdown estimates & forecasts, 2017-2027
10.2.2. Canada Generic Injectable Market
10.3. Europe Generic Injectable Market Snapshot
10.3.1. U.K. Generic Injectable Market
10.3.2. Germany Generic Injectable Market
10.3.3. France Generic Injectable Market
10.3.4. Spain Generic Injectable Market
10.3.5. Italy Generic Injectable Market
10.3.6. Rest of Europe Generic Injectable Market
10.4. Asia-Pacific Generic Injectable Market Snapshot
10.4.1. China Generic Injectable Market
10.4.2. India Generic Injectable Market
10.4.3. Japan Generic Injectable Market
10.4.4. Australia Generic Injectable Market
10.4.5. South Korea Generic Injectable Market
10.4.6. Rest of Asia Pacific Generic Injectable Market
10.5. Latin America Generic Injectable Market Snapshot
10.5.1. Brazil Generic Injectable Market
10.5.2. Mexico Generic Injectable Market
10.6. Rest of The World Generic Injectable Market

Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. Samsung Biologics Co Ltd
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Aurobindo Pharma Limited
11.2.3. Sun Pharmaceutical Industries Ltd.
11.2.4. Novartis AG
11.2.5. Merck & Co. Inc.
11.2.6. Cipla Ltd
11.2.7. Pfizer Inc
11.2.8. Fresenius Kabi
11.2.9. Sanofi S.A
11.2.10. AstraZeneca Plc
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption

The study of the market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. Our analysts contact company executives, managers, key opinion leaders, and industry experts. This enables our analyst to derive the closest possible figures without any major deviations in the actual number.

Primary Research Sources:

  • Interview conducted with raw material suppliers & manufacturers.
  • Interview conducted with manufacturers, suppliers & distributors, researchers, & representatives of regulatory bodies.
  • Interview conducted with market players, industry experts, & independent consultants.
  • Secondary Research Sources:
  • Purchased Database: D&B Hoovers, Bloomberg, Inc., Business Information Industry Association, NAICS Association.
  • Internal Database: White papers, Certified Publications, Articles by Recognized Authors and Regulatory Bodies.
  • Government Databases: Food and Agriculture Organization (FAO), European Industrial Hemp Association (EIHA), World Health Organization (WHO), Food and Drug Administration (FDA), International Telecommunication Union (ITU), United States Department of Agriculture (USDA), International organization of Motor Vehicle Manufacturers (OICA).

Need Assistance

Contact Person -
Krishant Mennon
Call us @
+ 91 99931 15879
Email: sales@bizwitresearch.com

Checkout

Why Choose Us?

Quality over Quantity

Backed by 60+ paid data sources our reports deliver crisp insights with no compromise quality.

Analyst Support

24x7 Chat Support plus
free analyst hours with every purchase

Flawless Methodology

Our 360-degree approach of market study, our research methods leave stones unturned.

Enquiry Now